ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IL-2 Mutein/Fc Fusion Protein HM16390

Its studies are led by Hanmi Pharmaceutical.

Furthest: phase 1, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Jul 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical11 open or runningphase 1since Nov 29, 2024Nov 29, 2024Jul 2031phase 1 · NCT06724016

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2024First study: phase 1 study in Advanced or Metastatic Solid TumorsFirst studyNCT06724016 · 292 planned · United States, South Korea

Ahead

  1. Jul 2031Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsNCT06724016

TargetBeta

IL2 →read by rule
“A recombinant fusion protein and long-acting analog of the human cytokine interleukin 2 (IL-2; IL2) consisting of a variant form of IL-2, IL-2 mutein, ”NCIt, by rule

Other programs on IL2

ProgramCompanyFurthest phaseStudies
darleukinrulePhilogenphase 39
daromunrulePhilogenphase 36
Daxokafusp AlfaSanofiphase 22
SAR444336Sanofiphase 22
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 12
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleoutpace-bio-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06724016Advanced or Metastatic Solid Tumors · United States, South Korea1RecruitingJul 2031292

How it is read

Names in the registry

  • “HM16390”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.